Last reviewed · How we verify

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic — Portfolio Competitive Intelligence Brief

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
triptorelin, goserelin, leuprorelin triptorelin, goserelin, leuprorelin phase 3 GnRH agonist GnRH receptor Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  2. Abbott · 1 shared drug class
  3. Bayer · 1 shared drug class
  4. Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
  5. Chesapeake Urology Research Associates · 1 shared drug class
  6. Chong Qing Reproducive and Genetic Institute · 1 shared drug class
  7. Colorado Center for Reproductive Medicine · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic:

Cite this brief

Drug Landscape (2026). Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-de-investigaci-n-en-oncolog-a-radioter-pica-fundaci-n-espa-ola-de-onco. Accessed 2026-05-17.

Related